Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy

This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanou, Maria Ioanna, Karachaliou, Eleni, Chondrogianni, Maria, Moschovos, Christos, Bakola, Eleni, Foska, Aikaterini, Melanis, Konstantinos, Andreadou, Elisabeth, Voumvourakis, Konstantinos, Papathanasiou, Matilda, Boutati, Eleni, Tsivgoulis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821852/
https://www.ncbi.nlm.nih.gov/pubmed/35130960
http://dx.doi.org/10.1186/s42466-022-00172-1
_version_ 1784646484730314752
author Stefanou, Maria Ioanna
Karachaliou, Eleni
Chondrogianni, Maria
Moschovos, Christos
Bakola, Eleni
Foska, Aikaterini
Melanis, Konstantinos
Andreadou, Elisabeth
Voumvourakis, Konstantinos
Papathanasiou, Matilda
Boutati, Eleni
Tsivgoulis, Georgios
author_facet Stefanou, Maria Ioanna
Karachaliou, Eleni
Chondrogianni, Maria
Moschovos, Christos
Bakola, Eleni
Foska, Aikaterini
Melanis, Konstantinos
Andreadou, Elisabeth
Voumvourakis, Konstantinos
Papathanasiou, Matilda
Boutati, Eleni
Tsivgoulis, Georgios
author_sort Stefanou, Maria Ioanna
collection PubMed
description This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.
format Online
Article
Text
id pubmed-8821852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88218522022-02-08 Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy Stefanou, Maria Ioanna Karachaliou, Eleni Chondrogianni, Maria Moschovos, Christos Bakola, Eleni Foska, Aikaterini Melanis, Konstantinos Andreadou, Elisabeth Voumvourakis, Konstantinos Papathanasiou, Matilda Boutati, Eleni Tsivgoulis, Georgios Neurol Res Pract Letter to the Editor This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2. BioMed Central 2022-02-08 /pmc/articles/PMC8821852/ /pubmed/35130960 http://dx.doi.org/10.1186/s42466-022-00172-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter to the Editor
Stefanou, Maria Ioanna
Karachaliou, Eleni
Chondrogianni, Maria
Moschovos, Christos
Bakola, Eleni
Foska, Aikaterini
Melanis, Konstantinos
Andreadou, Elisabeth
Voumvourakis, Konstantinos
Papathanasiou, Matilda
Boutati, Eleni
Tsivgoulis, Georgios
Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
title Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
title_full Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
title_fullStr Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
title_full_unstemmed Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
title_short Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
title_sort guillain-barré syndrome and fulminant encephalomyelitis following ad26.cov2.s vaccination: double jeopardy
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821852/
https://www.ncbi.nlm.nih.gov/pubmed/35130960
http://dx.doi.org/10.1186/s42466-022-00172-1
work_keys_str_mv AT stefanoumariaioanna guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT karachalioueleni guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT chondrogiannimaria guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT moschovoschristos guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT bakolaeleni guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT foskaaikaterini guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT melaniskonstantinos guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT andreadouelisabeth guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT voumvourakiskonstantinos guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT papathanasioumatilda guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT boutatieleni guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy
AT tsivgoulisgeorgios guillainbarresyndromeandfulminantencephalomyelitisfollowingad26cov2svaccinationdoublejeopardy

Ejemplares similares